Navigating the Evolving Molecular Diagnostic Reimbursement Landscape to Optimize Coverage and Payment and Identify Opportunities

2013 has proven to be a year of paradigmatic shifts in molecular diagnostics reimbursement policy. In this session, we will review and analyze these key policy and payment developments and discuss how your company can optimize the adoption of novel molecular diagnostic tests by developing strategies that consider the dynamic and changing reimbursement landscape. The key learning objectives from this presentation are as follows:

- Understand the current coding landscape and potential payment rates for these lab services
- Learn the implications for the new McKesson/American Medical Association partnership
- Be aware of coding development for future next-generation sequencing technology
- Learn about the different levels of evidence that drive coverage for diagnostic tests